IL17A and cancer: The protumor effect of IL-17, supporting tumor angiogenesis, increases during the chronic phase of cancer and inflammation development, and overpowers anticancer effects, promoting the expansion of cytotoxic T lymphocytes and other immune cells fighting cancer [175,306].